Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome following Ticagrelor administration leading to serious complications.
Article Sidebar
Downloads
Submit your own article
Register as an author to reserve your spot in the next issue of the Medical Research Archives.
Author RegistrationJoin the Society
The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.
Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.
MembershipMain Article Content
Abstract
Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is rarely reported with administration of Ticagrelor. We report a case, where such complication developed after 7 days of Ticagrelor administration, leading to acute severe complications requiring hospitalization. There was airway and renal involvement with elevated inflammatory markers. On withdrawing Ticagrelor, there was rapid resolution of symptoms.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS) Semin Gutan Med Surg. 1996;15:250–257.
3. Callot V, Roujeau JC, Bagot M, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol. 1996;132:1315–1321.
4. Peyriere H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2006;155:422–428.
5. Newell B, Moinfar M, Mancini A, Nopper A. Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS) Pediatr Dermatol. 2009;26:536–46.
6. Comparison of Diagnostic Criteria and Determination of Prognostic Factors for Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome.Dong-Hyun Kim and Young-Il Koh. Allergy Asthma Immunol Res. 2014 May; 6(3): 216–221.
7. De Vriese AS, Philippe J, Van Renterghem DM, et al. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature. Medicine (Baltimore) 1995;74:144–51.
8. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol 1992;19:424–30.
9. Quinn KL, Connelly KA. First report of hypersensitivity to ticagrelor. Can J Cardiol. 2014;30:957.
10. Hypersensitivity to ticagrelor and low response to clopidogrel: a case report. Jing Dai, Shuzheng Lyu,corresponding author and Changjiang Ge. Asia Pac Allergy. 2017 Jan; 7(1): 51–53.